Projectes destacats

  • Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

    Investigador/a principal: Patricia Pérez Galán.
    Codi: EFA 123/1.
    Durada: 01/01/2024 - 31/12/2025
  • Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

    Codi: HR22-00395.
    Durada: 01/12/2022 - 30/11/2025
  • Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

    Codi: INT_Milken_FLF_22.
    Durada: 01/12/2022 - 30/11/2024
  • Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

    Codi: PID2021-124894OB-I00.
    Durada: 01/09/2022 - 31/08/2025
  • Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

    Investigador/a principal: Patricia Pérez Galán.
    Durada: 01/07/2021 - 01/07/2023
  • Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

    Investigador/a principal: Patricia Pérez Galán.
    Finançador: Janssen Pharmaceuticals .
    Durada: 01/01/2020 - 31/12/2020
  • Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

    Investigador/a principal: Maria Cinta Cid Xutgla, Patricia Pérez Galán.
    Finançador: Ministerio de Economia y Competitividad (MINECO) .
    Codi: SAF 2017- 88275-R.
    Durada: 01/01/2018 - 31/12/2020
  • Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

    Investigador/a principal: Patricia Pérez Galán.
    Finançador: INTERREG V-POCTEFA .
    Codi: EFA281/16.
    Durada: 01/01/2018 - 31/12/2021
  • Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

    Investigador/a principal: Patricia Pérez Galán.
    Finançador: Ministerio de Economía y Competitividad .
    Codi: SAF 2014/57708R.
    Durada: 01/01/2015 - 01/01/2018
  • Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors

    Investigador/a principal: Patricia Pérez Galán.
    Finançador: Gilead .
    Durada: 01/07/2014